Abstract 962P
Background
Stereotactic radiotherapy (SBRT) has shown promising for unresectable hepatocellular carcinoma (HCC) due to its ability to modulate the tumor immune microenvironment. Methyl-CpG binding domain protein 3 (MBD3) is highly expressed in HCC and negatively correlated with prognosis. However, the role of MBD3 in the radioimmunology of SBRT in HCC remains unclear.
Methods
The expression and correlation of MBD3 and programmed cell death ligand 1 (PD-L1) were analyzed in HCC tissues before and after SBRT by immunohistochemistry (IHC). The mechanic regulations of MBD3 in the radioimmunology of SBRT in HCC were investigated both in vitro and in vivo studies.
Results
We observed a significant increase of PD-L1 in HCC after SBRT, which was associated with decreased MBD3 expression. As the radiation dose increased, MBD3 gradually degraded, while PD-L1 gradually upregulated in human and murine liver cancer cells. Through RNA sequencing, KEGG enrichment analysis and in vitro experiments, we identified that IL-6 was massively activated and released, leading to the activation of the JAK1/STAT3 signaling pathway, and ultimately resulted in the upregulation of PD-L1, which were induced by MBD3 degradation in liver cancer cells by irradiation. In vivo experiments showed that the combination of SBRT and PD-L1 blockade significantly enhanced the antitumor efficacy in the murine orthotopic model of HCC, partly dependent on the increased infiltration of IFNγ+CD8+T cells in the tumor. We also found that SBRT reactivated proteinase-activated receptor 2 (PAR2) to promote the release of IL-6, activating the JAK1/STAT3 signaling pathway, leading to the upregulation of PD-L1 through relieving the inhibition of F2RL1 (encoding PAR2) mediated by the deacetylation of the MBD3/NuRD complex. Our findings were further confirmed by IHC analysis of the above proteins in HCC tissues before and after SBRT.
Conclusions
Our study suggests that SBRT can reprogram the tumor immune microenvironment by activating the PAR2/IL-6/JAK1/STAT3 axis through MBD3 degradation, leading to PD-L1 upregulation, which may help develop new therapeutic strategies targeting PD-L1 to improve the efficacy of SBRT in HCC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
960P - Personalized circulating tumor DNA (ctDNA) monitoring for recurrence detection and treatment response assessment in hepatocellular carcinoma (HCC)
Presenter: Maen Abdelrahim
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18